Use and misuse of the concept of quality of life in evaluating surgical treatments for lower urinary tract symptoms

BJU International

Volumn 91, Issue 4, 2003, Pages 380-388

  Haltbakk, J ^a   Hanestad, B R ^a   Hunskaar, S ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

BPH; LUTS; Quality of life; Surgical treatment

Indexed keywords

ARTICLE; BIOMETRY; CLINICAL TRIAL; EVALUATION; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SYMPTOMATOLOGY; URINARY TRACT DISEASE; UROLOGIC SURGERY;

HEALTH STATUS; HUMANS; MALE; PROGNOSIS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; URINARY BLADDER NECK OBSTRUCTION; URINARY RETENTION;

EID: 0037351562     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04077.x     Document Type: Article

References (110)

1. Guyatt GH, Naylor CD, Juniper E, Heyland DK, Jaeschke R, Cook DJ. Users' guides to the medical literature XII. How to use articles about health-related quality of life. JAMA 1997; 277: 1232-6
2. Wood-Daupniee S. Assessing quality of life in clinical research: From where have we come and where are we going? J Clin Epidemiol 1999; 52: 355-63
3. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcome. JAMA 1995; 273: 59-65
4. Pennebaker JW. The Psychology of Physical Symptoms. New York: Springer-Verlag NY Inc, 1982
5. Anonymous. The world health organization quality of life assessment (WHOQoL): Position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403-9
6. Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Hanley D. Symptom status and quality of life following prostatectomy. JAMA 1988; 259: 3018-22
7. Epstein RS, Deverka PA, Chute CG et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 1431-45
8. Cockett AT, Aso Y, Denis L et al. World Health Organisation consensus committee recommendations concerning prostate symptom score (WHO-PSS) and quality of life assessment. 2. Diagnostic work-up of patients presenting with symptoms suggestive of prostatism. 3. Patient evaluation for research studies. Prog Urol 1991; 1: 957-72
9. Anonymous. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993; 150: 1696-700
10. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36
11. Tsukamoto T, Kumamoto Y, Masumori N et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995; 154: 391-5
12. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9
13. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
14. Sagnier P-P, MacFarlane G, Richard F, Botto H, Teillac P, Boyle P. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994; 151: 1266-70
15. Doll HA, Black NA, Flood AB, McPherson K. Patient-perceived health status before and up to 12 months after transurethral resection of the prostate for benign prostatic hypertrophy. Br J Urol 1993; 71: 297-305
16. Doll HA, Black NA, McPherson K, Williams GB, Smith JC. Differences in outcome of transurethral resection of the prostate for benign prostatic hypertrophy between three diagnostic categories. Br J Urol 1993; 72: 322-30
17. Thorpe AC, Clear R, Coles J, Neal DE. Nottingham Health Profile measurement in the assessment of clinical outcome after prostatectomy. Br J Urol 1995; 76: 446-50
18. MacDonagh RP, Cliff AM, Speakman MJ, O'Boyle PJ, Ewings P, Gudex C. The use of generic measures of health-related quality of life in the assessment of outcome from transurethral resection of the prostate. Br J Urol 1997; 79: 401-8
19. Hunter DJW, McKee CM, Black NA, Sanderson CFB. The impact of lower urinary tract symptoms on general health status and on the use of prostatectomy. Qual Life Res 1995; 4: 335-41
20. Jenkinson C, Gray A, Doll H, Lawrence K, Keoghane S, Layte R. Evaluation of index and profile measures of health status in a randomized controlled trial. Med Care 1997; 35: 1109-18
21. Litwin MS. Health related quality of life in older men without prostate cancer. J Urol 1999; 161: 1180-4
22. Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 1997; 157: 1711-7
23. Donovan J, Kay H, Abrams P, de la Rosette JJMCH, Brookes S, Kinn A-C. Measuring quality of life in men with urinary symptoms: Using the SF-36. Neurourol Urodyn 1995; 14: 559-60
24. Hunter DJW, McKee M, Black NA, Sanderson CFB. Health status and quality of life of British men with lower urinary tract symptoms: Results form SF-36. Urology 1995; 45: 962-71
25. Donovan JL, Kay HE, Peters TJ et al. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' study group. Br J Urol 1997; 80: 712-21
26. Arocho R, McMillian CA, Sutton-Wallace P. Construct validation of the USA-Spanish version of the SF-36 health survey in a Cuban-American population with benign prostatic hyperplasia. Qual Life Res 1998; 7: 121-6
27. Keoghane SR, Lawrence KC, Jenkonson CP, Doll HA, Chappel DB, Cranston DW. The Oxford laser prostate trial. Sensitivity to change of three measures of outcome. Urology 1996; 47: 43-7
28. Carter A, Sells H, Speakman M, Ewings P, O'Boyle P, MacDonagh RP. Quality of life changes following KTP/Nd:YAG laser treatment of the prostate and TURP. Eur Urol 1999; 36: 92-8
29. Trueman P, Hood SC, Nanyak USL, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in UK. BJU Int 1999; 83: 410-5
30. Abrams P, Donovan J, Kerrebroek van P, Schaefer W, Thuroff J, Neal D. The ICS-BPH study. Background and design. Neurourol Urodyn 1994; 13: 483-4
31. Abrams P, Donovan JL, Rosette de la JJMCM, Schaefer W. The International Continence Society 'Benign Prostatic Hyperplasia' study. Background, aims and methodology. Neurourol Urodyn 1997; 16: 79-91
32. Epstein RS, Deveka PA, Chute CG et al. Urinary symptom and quality of life questions indicative of obstructive benign prostatic hyperplasia. Results of a pilot study. Urology 1995; 28 (1 suppl): 20-6
33. Hald T, Nordling J, Andersen JT, Bilde T, Meyhoff HH, Walter S. A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol 1991; 138: 59-62
34. Brooks RG, Jendteg S, Lindgren B, Persson U, Bjork S. EuroQol. Health-related quality of life measurement. Results of the Swedish questionnaire exercise. Health Policy 1991; 18: 37-48
35. Goldberg DP, Williams P. User's Guide to the General Health Questionnaire. Windsor: NFER-Nelson, 1988
36. Brook RH, Ware JE, Davies-Avery A et al. Conceptualization and Measurement of Health for Adults in Health Insurance Study. Santa Monica: The RAND Corporation, 1979
37. Barry MJ, Fowler FJ, O'Leary MP et al. The American Urologic Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-57
38. Ware JE, Davies A. Scoring the Short-Form Mental Health Inventory (MH-5). Santa Monica: The RAND Corporation, 1983
39. Veit CT, Ware EJ. The structure of psychological distress and well-being in general populations. J Consult Clin Psych 1983; 51: 731-42
40. Dupuy HJ. The psychological general well-being (PGWB) index. In Wenger NK, Mattson ME, Furberg EJ eds, Assessment of Quality of Life in Clinical Trials. New York: Le Jacq Publishing, 1984
41. Hunt SM, McEwen J, McKenna SP. Measuring health status. A new tool for clinicians and epidemiologists. J Coll General Pract 1985; 35: 185-8
42. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care 1992; 30: 473-83
43. Barry MJ, Fowler FJ, O'Leary M et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Medical Care 1995; 33: AS145-55
44. Chacko N, Donovan JL, Abrams P et al. Transurethral prostatic resection or laser therapy for men with acute urinary retention: The CLasP randomized trial. J Urol 2001; 166: 166-70
45. Donovan JL, Peters TJ, Neal DE et al. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. J Urol 2000; 164: 65-70
46. Floratos DL, Kiemeney LALM, Rossi C, Kortmann BBM, Debruyne MJ, de la Rosette JJMCH. Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001; 165: 1533-8
47. Hammadeh MY, Fowlis GA, Singh M, Philp T. Transurethral electrovaporization of the prostate - a possible alternative to transurethral resection: a 1-year follow-up of a prospective randomized trial. Br J Urol 1998; 81: 721-5
48. Hakenberg OW, Pinnock CB, Marshall VR. Does evaluation with the International Prostate Symptom Score predict the outcome of transurethral resection of the prostate? J Urol 1997; 158: 94-9
49. Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN, Fraundorfer MR. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup. J Urol 1999; 162: 1640-4
50. Hindley RG, Mostafid AH, Brierly RD, Harrison NW, Thomas PJ, Fletcher MS. The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. BJU Int 2001; 88: 217-20
51. Hammadeh MY, Madaan S, Singh M, Philp T. A 3-year follow-up of a prospective randomized trial comparing transurethral electrovaporization of the prostate with standard transurethral prostatectomy. BJU Int 2000; 86: 648-51
52. Ekengren J, Haendler L, Hahn RG. Clinical outcome 1 year after transurethral vaporization and resection of the prostate. Urology 2000; 55: 231-5
53. Okada T, Terai A, Terachi T, Okada Y, Yoshida O. Transurethral electrovaporization of the prostate: Preliminary clinical results with pressure-flow analysis. Int J Urol 1998; 5: 55-60
54. Harewood LM, Cleeve LK, O'Connell HE, Pope AJ, Vaughan MG, Agarwal D. Transurethral needle ablation of the prostate (TUNA): clinical results and ultrasound, endoscopic, and histologic findings in pilot study of patients in urinary retention. J Endourol 1995; 9: 407-12
55. Holmes MA, Stewart J, Bou ton JB, Chambers RM. Transurethral needle ablation of the prostate: outcome at 1 year. J Endourol 1999; 13: 745-50
56. Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: Early clinical experience. Urology 1995; 45: 28-33
57. Murai M, Tachibana M, Miki M, Shiozawa H, Hirao Y, Okajima E. Transurethral needle ablation of the prostate: An initial japanese clinical trial. Int J Urol 2001; 8: 99-105
58. Kahn SA, Alphonse P, Tewari A, Narayan P. An open study on the efficacy and safety of transurethral needle ablation of the prostate in treating symptomatic benign prostatic hyperplasia: The University of Florida experience. J Urol 1998; 160: 1695-700
59. Zlotta AR, Peny M-O, Matos C, Schulman CC. Transurethral needle ablation of the prostate: clinical experience in patients in urinary acute retention. Br J Urol 1996; 77: 391-7
60. Namiki K, Shiozawa H, Tsuzuki M, Mamiya T, Miki M. Efficacy of transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia. Int J Urol 1999; 6: 341-5
61. Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology 1997; 49: 847-50
62. Millard RJ, Harewood LM, Tamaddon K. A study of the efficacy and safety of transurethral needle ablation (TUNA) treatment for benign prostatic hyperplasia. Neurourol Urodyn 1996; 15: 619-29
63. Roehrborn CG, Burkhard FC, Bruskewitz RC et al. The effect of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study. J Urol 1999; 162: 92-7
64. Roehrborn CG, Issa MM, Bruskewitz C et al. Transurethral needle ablation for benign prostatic hyperplasia: 12 month results of a prospective, multicentre study. Urology 1998; 51: 415-21
65. Rosario DJ, Woo H, Potts KL, Cutinha PE, Hastie KJ, Chapple CR. Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 1997; 80: 579-86
66. Ramon J, Lynch TH, Eardley I et al. Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study. Br J Urol 1997; 80: 128-35
67. Arai Y, Aoki Y, Okubo K et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000; 164: 1206-11
68. Chahal R, Sundaram SK, Gogoi NK. Assessment of voiding outcome, sexual function and quality of life two years following KTP/YAG hybrid laser prostatectomy. Urol Int 2000; 65: 125-9
69. Arai Y, Ishitoya S, Okubu K, Suzuki Y. Transurethral interstitial laser coagulation for benign prostatic hyperplasia. Treatment outcome and quality of life. Br J Urol 1996; 78: 93-8
70. Matsuoka K, Iida S, Tomiyasu K, Shimada A, Noda S. Transurethral holmium laser resection of the prostate. J Urol 2000; 163: 515-8
71. Gilling PJM, Kennett KM, Fraundorfer MR. Holmium laser resection v transurethral resection of the prostate: Results of a randomized trial with 2 years of follow-up. J Endourol 2000; 14: 757-60
72. Slaa te E, Francisca EAE, Hendriks JCM, Kiemeney LALM, Debruyne FMJ, Rosette de la JJMCH. Quality-of-life assessment in patients after laser prostatectomy. Br J Urol 1997; 80: 211-6
73. Kitagawa M, Furuse H, Fukuta K, Aso Y. Holmium:YAG Jaser resection of the prostate versus visual laser ablation of the prostate and transurethral ultrasound-guided laser induced prostatectomy: a retrospective comparative study. Int J Urol 1998; 5: 152-6
74. Eliasson T, Damber J-E. Temperature controlled high energy transurethral microwave thermotherapy for benign prostatic hyperplasia using a heat shock strategy. J Urol 1998; 160: 777-82
75. Eliasson T, Abramson L, Damber J-E. Importance of thermal dose and antenna location in transurethral microwave thermotherapy for benign prostatic hyperplasia. J Endourol 1998; 12: 581-9
76. Sugiyama T, Park YC, Hanai T, Ohnishi N, Kurita T. Why is transurethral microwave thermotherapy (TUMT) positively effective? Int J Urol 1998; 30:293-300
77. Djavan B, Seitz C, Roehrborn CG et al. Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. Urology 2001; 57: 66-70
78. Djavan B, Shariat S, Fakhari M et al. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. Urology 1999; 53: 251-9
79. Larson TR, Blute ME, Bruskewitz R, Mayer RD, Ugarte RR, Utz WJ. A high-energy microwave thermoablation system for the treatment of benign prostatic hyperplasia: Results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial. Urology 1998; 51: 731-42
80. Terada N, Aoki Y, Ichioka K et al. Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave. Response durability and variables potentially predicting response. Urology 2001; 57: 701-5
81. Djavan B, Roehrborn G, Shariat S, Ghawidel K, Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus a -blocker treatment of patients with benign prostatic hyperplasia. J Urol 1999; 161: 139-43
82. Eliasson T, Damber J-E, Teriø H. Pressure-flow studies before and after transurethral microwave thermotherapy of benign prostatic hyperplasia using low- and high-energy protocols. Br J Urol 1998; 82: 513-9
83. Dæhlin L, Frugård J. Three-year follow-up after transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia using the Primus u + r device. Scand J Urol Nephrol 1999; 33: 217-21
84. Diavan B, Shariat S, Schaefer B, Marberger M. Tolerability of high energy transurethral microwave thermotherapy with topical anesthesia: Results of a prospective, randomized, single-blinded clinical trial. J Urol 1998; 160: 772-6
85. Terai A, Arai Y, Onishi H, Oishi K, Takeuchi H, Yoshida O. Transurethral microwave thermotherapy for benign prostatic hyperplasia: Clinical results after a 1-year follow-up. Int J Urol 1995; 2: 24-8
86. Terai A, Shichiri Y, Onishi H et al. Increasing the thermal dose in transurethral microwave thermotherapy produces no improvement in therapeutic efficacy. Int J Urol 1995; 2: 186-90
87. Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001; 166: 172-5
88. Muschter R, Schorsch I, Danielli L et al. Transurethral water-induced thermotherapy for the treatment of benign prostatic hyperplasia: a prospective multicenter clinical trial. J Urol 2000; 164: 1565-9
89. Uchida T, Yokoyama E, Iwamura M et al. High intensity ultrasound for benign prostatic hyperplasia. Int J Urol 1995; 2: 181-5
90. Uchida T, Muramoto M, Kyunou H, Iwamura M, Egawa S, Koshiba K. Clinical outcome of high-intensity focused ultrasound for treating benign prostatic hyperplasia: Preliminary report. Urology 1998; 52: 66-71
91. Arai Y, Okubo K, Okada T, Maekawa S, Aoki Y, Maeda H. Interstitial laser coagulation for management of benign prostatic hyperplasia: a Japanese experience. J Urol 1998; 159: 1961-5
92. Emberton M, Neal DE, Black N et al. The effect of prostatectomy on symptom severity and quality of life. J Urol 1996; 77: 301-16
93. Eri LM, Tveter KJ. Measuring the quality of life of patients with benign prostatic hyperplasia. Eur Urol 1992; 21: 257-62
94. Fowler FJ. Patient reports of symptoms and quality of life following prostate surgery. Eur Urol 1991; 20: 44-9
95. Mozes B, Cohen YC, Olmer L, Shabtai E. Factors affecting change in quality of life after prostatectomy for benign prostatic hypertrophy: The impact of surgical techniques. J Urol 1996; 155: 191-6
96. Quek KF, Low WY, Razack AH, Loh CS. The psychological effects of treatment for lower urinary tract symptoms. BJU Int 2000; 86: 630-3
97. Yamamoto M, Hibi H, Miyake K. A comparison of transurethral resection of the prostate and medical treatment for the patient with moderate symptoms of benign prostatic hyperplasia. Nagoya J Med Sci 1996; 59: 11-6
98. Francisca EAE, D'Ancona FCH, Hendriks JCM, Kiemeney LALM, Debruyne FMJ, Rosette de la JJMCH. Quality of life assessment in patients treated with lower energy thermotherapy (Prostasoft 2.0): Results of a randomized transurethral microwave thermotherapy versus sham study. J Urol 1997; 158: 1839-44
99. Meyhoff H-H, Hald T, Nordling J, Andersen JT, Bride T, Wather S. A new patient weighted symptom score system (DAN-PSS- 1). Scand J Urol Nephrol 1993; 27: 493-9
100. Hansen BJ, Flyger H, Mortensen S, Mensink HJA, Meyhoff H-H. Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the danish prostatic symptom score (DAN-PSS-1) system. Scand J Urol Nephrol 1996; 30: 103-7
101. Flyger HL, Holm NR, Nielsen R, Mortensen S. The symptomatic outcome of transurethral prostatectomy evaluated with the DAN-PSS-1 score system. Scand J Urol Nephrol 1996; 30: 45-9
102. Issa MM. Transurethral needle ablation of the prostate: Report of initial United States clinical trial. J Urol 1996; 156: 413-9
103. Issa MM, Perez-Brayfield M, Petros JA, Anastasia K, Labadia AJ, Miller LE. A prospective study of transperineal prostatic block for transurethral needle ablation for benign prostatic hyperplasia: The Emory University experience. J Urol 1999; 162: 1636-9
104. Bruskewitz R, Issa MM, Roehrborn CG et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998; 159: 1588-94
105. Spilker B. Quality of Life Assessments in Clinical Trials. New York: Raven Press, 1990
106. Krause NM, Jay GM. What do global self-rated health items measure? Med Care 1994; 32: 930-42
107. Smith KW, Avis NE, Assmann SF. Distinguishing between quality of life and health status in quality of life research: a meta-analysis. Qual Life Res 1999; 8: 447-59
108. Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology 1999; 53: 1090-8
109. Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research. How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770-4
110. Girman CJ, Kolman C, Liss CL, Bolognese JA, Binkowitz BS, Stoner E. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Prostate 1996; 29: 83-90